HHS releases fertility benefits proposed rule 

The Centers for Medicare & Medicaid Services (CMS), an agency operating under the U.S. Department of Health and Human Services (HHS), has published a proposed rule that introduces a new legal framework for employers to offer supplemental fertility care benefits. This initiative, announced by the administration as an expansion of fertility coverage, has drawn attention for its nature as an optional pathway rather than a mandate, and for its potential implications for the scope and accessibility of assisted reproductive technologies (ART), particularly in vitro fertilization (IVF).

The proposed rule, published in the Federal Register on May 13, 2026, under the document number 2026-09479, aims to clarify how employers can provide fertility benefits without violating existing regulations, particularly those pertaining to health insurance. Historically, employers have faced complexities in offering comprehensive fertility treatments due to varying state laws and the intricate nature of health insurance coverage. This new pathway is intended to provide a clearer legal structure for such offerings.

However, a significant point of contention raised by reproductive rights advocates is that the rule grants employers the option to offer these benefits, not a requirement. This means that access to fertility care, including crucial treatments like IVF, will remain dependent on employer discretion. Furthermore, the rule does not extend coverage for fertility treatments to public health insurance programs such as Medicaid, which currently has limited provisions for ART. This disparity in access is a key concern for organizations advocating for broader reproductive healthcare access.

Background and Context: The Evolving Landscape of Fertility Care and Employer Benefits

The development of this proposed rule occurs against a backdrop of increasing awareness and demand for fertility treatments. Infertility affects a significant portion of the population, with estimates suggesting that approximately 15% of couples in the United States experience infertility. As medical advancements have made ART more accessible and successful, the demand for coverage has grown. However, employer-sponsored health insurance has historically lagged in providing comprehensive fertility benefits.

Historically, fertility benefits have been an "add-on" or a carve-out, often excluded from standard health insurance plans. When offered, coverage has frequently been limited in scope, duration, or number of cycles, and often excludes certain advanced technologies. This has created a fragmented system where access to fertility treatment is largely determined by employment status, the specific employer’s benefits package, and geographic location, as state mandates for fertility coverage vary widely.

The push for expanded fertility coverage has also been fueled by a growing understanding of infertility as a medical condition rather than a lifestyle choice. For many individuals and couples, infertility can be a source of significant emotional, psychological, and financial distress. ART, including IVF, has become a vital tool for those seeking to build families.

Proposed Rule Details and Potential for Restricted Coverage

A critical aspect of the proposed rule that has drawn significant criticism is the potential for employers to offer "restricted IVF" or other approaches to fertility healthcare that may not align with a comprehensive understanding of reproductive health. Critics argue that under this new pathway, employers could choose to cover only certain aspects of fertility treatment, potentially excluding IVF altogether or offering coverage with severe limitations.

These limitations could include:

• Exclusion of IVF: Employers might choose to cover only less technologically advanced fertility treatments, such as ovulation induction or intrauterine insemination (IUI), while omitting IVF, which is often the most effective treatment for many forms of infertility.
• Emphasis on "Lifestyle Factors": The proposed rule could inadvertently permit or encourage benefit plans that attribute infertility to "lifestyle factors" rather than underlying medical conditions. This approach can place undue blame on individuals seeking treatment and may lead to coverage that requires patients to demonstrate "lifestyle changes" before accessing medical interventions.
• Discouraging IVF Use: Benefit designs could be structured to make IVF prohibitively expensive or to impose such stringent pre-authorization requirements that its use is discouraged, even for individuals for whom it is the medically recommended course of action.
• Focus on "Natural" Conception: Some benefit plans might prioritize treatments that encourage natural conception and discourage the use of ART, potentially overlooking the medical necessity of IVF for certain diagnoses.

The language used by President Trump during the announcement of the new rule has amplified these concerns. He reportedly stated that the rule would "hopefully reduce the number of couples who ultimately need to resort to IVF." This statement has been interpreted by reproductive rights organizations as an indication that the administration’s intent may be to steer individuals away from IVF, rather than to ensure equitable access to it. IVF is currently the most common and one of the most effective methods of assisted reproductive technology, playing a crucial role in helping individuals build their families.

Reactions and Analysis from Stakeholders

Reproductive rights organizations have been vocal in their criticism of the proposed rule. The Center for Reproductive Rights, for instance, has highlighted that while the rule provides an optional pathway, it does not mandate coverage and allows for potentially restrictive benefit designs. Their analysis emphasizes that the rule does not address the fundamental issue of access to ART within public insurance programs like Medicaid, leaving many vulnerable populations without essential coverage.

"This proposed rule offers a glimmer of choice for some employers, but it falls far short of ensuring equitable access to fertility care," stated a spokesperson for a leading reproductive rights organization. "The real concern lies in the potential for employers to cherry-pick which treatments to cover, potentially favoring less effective or more restrictive options over IVF, which is a critical tool for many individuals and couples struggling with infertility. Furthermore, the lack of any movement to expand coverage for IVF within public health insurance programs is a significant missed opportunity."

Conversely, some employer groups and benefits consultants may view the proposed rule as a positive step forward, offering clarity and a framework for employers who wish to provide fertility benefits. For companies that have been hesitant to offer such benefits due to legal ambiguities, this proposed rule could provide the necessary guidance to implement or expand their offerings.

"The clarity provided by CMS in this proposed rule is valuable for employers seeking to navigate the complex landscape of fertility benefits," commented a representative from a national benefits advisory firm. "It offers a defined pathway that should reduce some of the legal uncertainties that have previously hindered the adoption of comprehensive fertility coverage. However, the ultimate scope of coverage will, as always, be a decision for individual employers to make based on their resources and their employees’ needs."

Broader Implications and the Path Forward

The proposed rule represents a complex interplay between federal guidance, employer autonomy, and the ongoing advocacy for reproductive healthcare access. While it acknowledges the growing importance of fertility benefits, its optional nature and the potential for restricted coverage raise significant questions about its impact on actual access to care.

Key implications include:

• Continued Disparities in Access: The rule is unlikely to eliminate the significant disparities in fertility coverage that currently exist. Employees of companies that choose not to offer benefits, or those that offer limited coverage, will continue to face financial barriers to treatment.
• Potential for "Coverage Shopping": Employers may be able to design benefit plans that offer seemingly attractive fertility benefits, but which are structured to limit actual utilization of expensive treatments like IVF, thereby controlling costs.
• Focus on Public Insurance: The absence of any provision for expanding fertility coverage within Medicaid or Medicare means that low-income individuals and families will likely remain excluded from the benefits of ART. This raises questions of equity and access to family-building options.
• Ongoing Advocacy: Reproductive rights organizations are likely to continue their efforts to advocate for mandates for comprehensive fertility coverage, both in employer-sponsored insurance and in public health programs. The proposed rule may serve as a catalyst for further legislative and regulatory action.

The Federal Register notice provides a period for public comment, during which stakeholders can submit their feedback on the proposed rule. This period is crucial for shaping the final regulations and for ensuring that the concerns of patients, providers, and advocacy groups are addressed. The final rule, when published, will provide a clearer picture of the landscape of employer-sponsored fertility benefits in the United States, and its ultimate impact will depend on how employers choose to utilize the pathways it creates, and on the continued advocacy for broader access to reproductive healthcare.

The debate surrounding this proposed rule underscores the evolving nature of reproductive healthcare and the persistent challenges in ensuring that essential medical treatments are accessible to all who need them, regardless of their employment status or financial circumstances. As the administration seeks to provide options for employers, advocates emphasize the need for a more robust and equitable approach to fertility coverage that prioritizes patient well-being and the fundamental right to build a family.